Physician profile
Amit Bajaj
NPI 1144783143
$1,437.31
in general payments reported to CMS, 2019-2025
14 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $396 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257 · Travel and Lodging: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.85 |
| Travel and Lodging | $180.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $510.43 | 2023-2025 | Clareon, Centurion, Rhopressa |
| Dompe US, INC. | $146.51 | 2024-2025 | Oxervate |
| Glaukos Corporation | $144.04 | 2024-2025 | Idosetr, Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Shield Therapeutics INC | $120.85 | 2024-2025 | |
| Abbvie INC. | $106.34 | 2023-2025 | Durysta |
| Amgen INC. | $81.12 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $75.97 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $68.47 | 2023-2024 | Acthar |
| Merck Sharp & Dohme LLC | $46.99 | 2024-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $39.32 | 2023-2024 | Shingrix |
| Harrow Eye, LLC | $35.90 | 2025 | Vevye |
| Thea Pharma INC. | $26.59 | 2023-2024 | Iyuzeh |
| Sight Sciences, INC. | $18.49 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Ultragenyx Pharmaceutical INC. | $16.29 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.